论文部分内容阅读
目的观察小剂量糖皮质激素布地奈德吸入治疗支气管哮喘的临床效果。方法将支气管哮喘患者112例以随机抽样的方法分为试验组与对照组,各56例。对照组患者接受全身糖皮质激素常规治疗,试验组接受小剂量布地奈德吸入治疗,对比2组患者肺部功能改善情况以及临床效果。结果试验组总有效率为98.21%显著高于对照组的76.79%,差异有统计学意义(P<0.01)。治疗后2组Paw、Gaw水平均改善,且试验组改善程度大于对照组,差异均有统计学意义(P<0.05)。结论对支气管哮喘患者予以小剂量糖皮质激素布地奈德具有较为显著的临床效果,能够有效降低患者的Raw,提高Gaw,进而改善患者的肺部功能,使得哮喘患者能够长时间处于一个较为稳定的状态,可广泛用于临床治疗。
Objective To observe the clinical effect of low dose glucocorticoid budesonide inhalation in the treatment of bronchial asthma. Methods A total of 112 patients with bronchial asthma were randomly divided into experimental group and control group with 56 cases in each group. Patients in the control group received conventional glucocorticoid therapy. Patients in the test group received low-dose budesonide inhalation. The lung function improvement and clinical outcomes were compared between the two groups. Results The total effective rate was 98.21% in the experimental group was significantly higher than 76.79% in the control group, the difference was statistically significant (P <0.01). After treatment, the Paw and Gaw levels were improved in both groups, and the improvement in the experimental group was greater than that in the control group, with significant differences (P <0.05). Conclusions The low-dose glucocorticoid budesonide in patients with bronchial asthma has a significant clinical effect, which can effectively reduce Raw, increase Gaw, and improve lung function in patients with asthma, enabling patients with asthma to be in a stable state for a long time State, can be widely used in clinical treatment.